--- title: Department of War Pharmacy Uniform Formulary Blanket Purchase… | Due Oct 26, 2026 - MatchAwards description: Department of War Pharmacy Uniform Formulary Blanket Purchase Agreement / Uniform Formulary Additional Discount Program. DEFENSE HEALTH AGENCY (DHA). Solicitation HT9402-26-Q-9404. NAICS 325412 - Pharmaceutical Preparation Manufacturing. Deadline 2026-10-26. The Department of War (DoW) is... canonical: https://matchawards.com/defense_health_agency_dha/posts/117407498512219382 og:image: https://matchawards.com/home_logo.png og:image:width: 130 og:image:height: 130 twitter:card: MatchAwards.com twitter:image: https://matchawards.com/home_logo.png og:site_name: MatchAwards og:type: article og:title: Department of War Pharmacy Uniform Formulary Blanket Purchase… | Due Oct 26, 2026 og:url: https://matchawards.com/defense_health_agency_dha/posts/117407498512219382 og:description: Department of War Pharmacy Uniform Formulary Blanket Purchase Agreement / Uniform Formulary Additional Discount Program. DEFENSE HEALTH AGENCY (DHA). Solicitation HT9402-26-Q-9404. NAICS 325412 - Pharmaceutical Preparation Manufacturing. Deadline 2026-10-26. The Department of War (DoW) is... og:image: https://matchawards.com/system/accounts/avatars/000/000/149/original/4a29a629b0aab3df.png?1639145829 og:image:width: 120 og:image:height: 120 twitter:card: summary --- # Department of War Pharmacy Uniform Formulary Blanket Purchase Agreement / Uniform Formulary Additional Discount Program Agency [DEFENSE HEALTH AGENCY (DHA)](/defense%5Fhealth%5Fagency%5Fdha) Office JBSA FT SAM HOUSTON, USA Notice type Solicitation Solicitation number HT9402-26-Q-9404 NAICS [325412 - Pharmaceutical Preparation Manufacturing](/groups/360) PSC 6505 - DRUGS AND BIOLOGICALS Category [Drugs and Pharmaceutical Products (10.1)](/categories/medical/drugs-and-pharmaceutical-products) Posted 2026-10-08 Deadline 2026-10-26 Place of performance San Antonio, Texas 78230, UNITED STATES ## Description The Department of War (DoW) is required by law (10 U.S.C. § 1074g) to establish an effective, efficient, integrated pharmacy benefits program for the Military Health System (MHS) which includes the purchase pharmaceutical agents. The law and implementing regulation (32 CFR Section 199.21) describe the process by which the DoW Pharmacy and Therapeutics (P&T) Committee will consider the relative clinical effectiveness and relative cost effectiveness of pharmaceutical agents in a therapeutic class in recommending the selection of agents for the DoW Uniform Formulary (UF) and, for cost sharing purposes, the classification of a pharmaceutical agent as generic, formulary, Basic Core Formulary (BCF), Extended Core Formulary (ECF), or non-formulary (NF). Prior to the scheduled P&T Committee meeting, a Request for Quotation (RFQ) for pharmaceutical agents within Drug Classes identified for placement on the UF has been issued to obtain quotes from industry. The Defense Health Agency may award Uniform Formulary Blanket Purchase Agreements (UF BPA) and the Uniform Formulary Additional Discount Program Agreements (UF ADP) based on the UF decision. This process is described in the attached RFQ. P&T COMMITTEE MEETING: The following November 2026 newly approved drugs will be reviewed: **a. Adquey - Atopic - Subclass: Topical Agents** **b. Armlupeg - White Blood Cell Stimulants - Subclass: Pegfilgrastims** **c. Beqalzi - Oncological Agents - Non-BTKI for Chronic Lymphocytic Leukemia-Small Lymphocytic Lymphoma** **d. Bixlenvo - Antiretrovirals - Subclass: Combinations** **e. Clotic - Antifungals - Subclass: NA** **f. Etcamah - Breast Cancer Agents - Estrogen Receptor Antagonist** **g. Langlara - Insulins - Subclass: Basal** **h. Lisraya - Targeted Immunomodulatory Biologics – NA** **i. Mimrylo - Hematological Agents – NA** **j. Nuzolvence - Antibiotics – NA** **k. Rasonque - Oncological Agents - Subclass: RAS Inhibitors** **l. Rezenopy - Alcohol Deterrants - Narcotic Antagonists** The RFQ, including UF BPA and UF ADP appendices are attached here in. The instructions, important deadlines, and points of contact are in document, RFQ HT9402-26-Q-9404. Pre-quotation teleconference is on October 14, 2026\. Details are stated in Part 2.4\. Pre-Quotation Teleconference. Responses to the clinical questions in Part 3.4 shall be submitted via e-mail to the RFQ POC in Part 2.3.1., no later than the date stated in Part 2.3.2. ## Attachments * [Attachment 1](https://sam.gov/api/prod/opps/v3/opportunities/resources/files/037231e100e946c88ba68a6554dab810/download) * [Attachment 2](https://sam.gov/api/prod/opps/v3/opportunities/resources/files/1542425c597f486095bb1fb95d8ab8d2/download) * [Attachment 3](https://sam.gov/api/prod/opps/v3/opportunities/resources/files/1d865dc35aa14bc19405ed6dcb4570af/download) * [Attachment 4](https://sam.gov/api/prod/opps/v3/opportunities/resources/files/204c6e03bf234be9b02d712e5f6acd9f/download) * [Attachment 5](https://sam.gov/api/prod/opps/v3/opportunities/resources/files/32d5d9d9a606456fbe268c0b6bf8cb92/download) * [Attachment 6](https://sam.gov/api/prod/opps/v3/opportunities/resources/files/37015ae3509f44b5ab1095f5fb0f7139/download) * [Attachment 7](https://sam.gov/api/prod/opps/v3/opportunities/resources/files/43864597bc754c69a8793b6548633bd3/download) * [Attachment 8](https://sam.gov/api/prod/opps/v3/opportunities/resources/files/775347de152449219017ea6fb96bebda/download) * [Attachment 9](https://sam.gov/api/prod/opps/v3/opportunities/resources/files/7b3faec391aa40b7b8b5efcad11fed1e/download) * [Attachment 10](https://sam.gov/api/prod/opps/v3/opportunities/resources/files/894b3461032c4c099ad254396c4e5aab/download) * [Attachment 11](https://sam.gov/api/prod/opps/v3/opportunities/resources/files/95a0d9e9dc84426f90c08ae9dc5922bc/download) * [Attachment 12](https://sam.gov/api/prod/opps/v3/opportunities/resources/files/a61aff9776d9466bb34f4a536437630d/download) * [Attachment 13](https://sam.gov/api/prod/opps/v3/opportunities/resources/files/a9d62a6a83254e91893bccf257008944/download) * [Attachment 14](https://sam.gov/api/prod/opps/v3/opportunities/resources/files/d71cced2216047c0bde97be8df972959/download) * [Attachment 15](https://sam.gov/api/prod/opps/v3/opportunities/resources/files/f2dc157f4e88412f89d6f1d375298eaf/download) * [Attachment 16](https://sam.gov/api/prod/opps/v3/opportunities/resources/files/fd7707bb286344d8bcef78e3dbc3df25/download) ## Contacts * Tracy Banks * Kirk Heyen Email and phone are in the source notice. [Source notice](https://sam.gov/workspace/contract/opp/1b4dc95103b348fe8d1f0aed614fc920/view) ```json {"@context":"https://schema.org","@type":"Demand","name":"Department of War Pharmacy Uniform Formulary Blanket Purchase Agreement / Uniform Formulary Additional Discount Program","description":"The Department of War (DoW) is required by law (10 U.S.C. § 1074g) to establish an effective, efficient, integrated pharmacy benefits program for the Military Health System (MHS) which includes the purchase pharmaceutical agents. The law and implementing regulation (32 CFR Section 199.21) describe the process by which the DoW Pharmacy and Therapeutics (P\u0026T) Committee will consider the relative clinical effectiveness and relative cost effectiveness of pharmaceutical agents in a therapeutic class in recommending the selection of agents for the DoW Uniform Formulary (UF) and, for cost sharing purposes, the classification of a pharmaceutical agent as generic, formulary, Basic Core Formulary (BCF), Extended Core Formulary (ECF), or non-formulary (NF). Prior to the scheduled P\u0026T Committee meeting, a Request for Quotation (RFQ) for pharmaceutical agents within Drug Classes identified for placement on the UF has been issued to obtain quotes from industry. The Defense Health Agency may award Uniform Formulary Blanket Purchase Agreements (UF BPA) and the Uniform Formulary Additional Discount Program Agreements (UF ADP) based on the UF decision. This process is described in the attached RFQ. P\u0026T COMMITTEE MEETING: The following November 2026 newly approved drugs will be reviewed: a. Adquey - Atopic - Subclass: Topical Agents b. Armlupeg - White Blood Cell Stimulants - Subclass: Pegfilgrastims c. Beqalzi - Oncological Agents - Non-BTKI for Chronic Lymphocytic Leukemia-Small Lymphocytic Lymphoma d. Bixlenvo - Antiretrovirals - Subclass: Combinations e. Clotic - Antifungals - Subclass: NA f. Etcamah - Breast Cancer Agents - Estrogen Receptor Antagonist g. Langlara - Insulins - Subclass: Basal h. Lisraya - Targeted Immunomodulatory Biologics – NA i. Mimrylo - Hematological Agents – NA j. Nuzolvence - Antibiotics – NA k. Rasonque - Oncological Agents - Subclass: RAS Inhibitors l. Rezenopy - Alcohol Deterrants - Narcotic Antagonists The RFQ, including UF BPA and UF ADP appendices are attached here in. The instructions, important deadlines, and points of contact are in document, RFQ HT9402-26-Q-9404. Pre-quotation teleconference is on October 14, 2026. Details are stated in Part 2.4. Pre-Quotation Teleconference. Responses to the clinical questions in Part 3.4 shall be submitted via e-mail to the RFQ POC in Part 2.3.1., no later than the date stated in Part 2.3.2.","url":"https://matchawards.com/defense_health_agency_dha/posts/117407498512219382","identifier":"HT9402-26-Q-9404","category":"325412 - Pharmaceutical Preparation Manufacturing","additionalProperty":[{"@type":"PropertyValue","propertyID":"PSC","name":"PSC","value":"6505 - DRUGS AND BIOLOGICALS"},{"@type":"PropertyValue","propertyID":"CM category","name":"Category Management category","value":"10.1 Drugs and Pharmaceutical Products","url":"https://matchawards.com/categories/medical/drugs-and-pharmaceutical-products"}],"availabilityStarts":"2026-10-08","availabilityEnds":"2026-10-26","areaServed":"San Antonio, Texas 78230, UNITED STATES","sameAs":"https://sam.gov/workspace/contract/opp/1b4dc95103b348fe8d1f0aed614fc920/view"} ```